Evidence map›Paper›PMID 40804221›Full record

ArticleAAPS PharmSciTech2025

Palatable Orally Disintegrating Tablets of Losartan Potassium Developed by Spray-drying Technique and Direct Compression Intended for Pediatric Use.

Candela Juan, Noelia Gonzalez Vidal, Loreana Gallo

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Candela JuanDepartamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS), San Juan 670, 8000, Bahía Blanca, Buenos Aires, Argentina.ORCID http://orcid.org/0000-0003-0299-9041
Noelia Gonzalez VidalDepartamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS), San Juan 670, 8000, Bahía Blanca, Buenos Aires, Argentina.ORCID http://orcid.org/0000-0002-0687-0096
Loreana GalloDepartamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS), San Juan 670, 8000, Bahía Blanca, Buenos Aires, Argentina. lgallo@plapiqui.edu.ar.ORCID http://orcid.org/0000-0001-8745-9620

Funding

Agencia Nacional de Laboratorios Públicos (ANLAP) EX-2020-50428127-APN-ANLAP#MSAgencia Nacional de Promoción Científica y Tecnológica PICT-2021-GRT-TI-00524Consejo Nacional de Investigaciones Científicas y Técnicas PIBAA 28720210100113COUniversidad Nacional del Sur PGI 24/B306Universidad Nacional del Sur PGI 24/B339
6 · The paper itself

Abstract

Several diseases that affect the pediatric population, e.g., heart diseases, cannot be efficiently treated because of the absence of a suitable dosage form. In this sense, orally disintegrating tablets (ODT) are solid dosage forms that are gaining acceptance. Losartan potassium (LP) is the drug of choice for managing pediatric arterial hypertension, although its bitter taste represents a major challenge to treatment compliance. To mitigate this drawback, this study aimed to develop palatable ODT, by the incorporation of spray-dried powders (SDP), composed of LP, Eudragit® polymers and adjuvants (i.e., colloidal silicon dioxide, mannitol, and PEG4000). The SDP were analyzed in terms of production yield and encapsulation efficiency. Selected SDP were incorporated into ODT by direct compression, and characterized in terms of mechanical and pharmaceutical properties, as well as palatability. Tablets with satisfactory disintegration time, hardness, and friability were obtained, though different performance during in vitro dissolution study. In the palatability study, the volunteer panel confirmed that the ODT-7SDP formulation, prepared by spray drying with Eudragit® E PO and colloidal silicon dioxide, showed a marked reduction in LP bitterness. In conclusion, the applied technologies successfully reduced the bitter taste of LP, enabling its oral administration in the form of ODT, particularly for pediatric patients.

Indexed as

LosartanTabletsAdministration, OralChemistry, PharmaceuticalChildDesiccationDrug CompoundingExcipientsHardnessHumansMannitolPolyethylene GlycolsPolymersPolymethacrylic AcidsPowdersSilicon DioxideExcipientsLosartanMannitolpolyethylene glycol 400Polyethylene GlycolsPolymersPolymethacrylic AcidsPowdersSilicon DioxideTabletsLosartan potassiumOrally disintegrating tabletPediatricSpray dryingTaste masking

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.